Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — Even in an election year dominated by a deadly pandemic and President Trump’s chaotic first term, Democrats in North Carolina are talking, unceasingly, about drug prices.

In a brutal series of attack ads, Democrats have painted incumbent Sen. Thom Tillis, a Republican, as a pro-pharma shill, even calling him “pharma’s favorite senator.” They’ve highlighted his status as a leading recipient of drug industry campaign cash and his recent opposition to a GOP-backed drug pricing bill. His Democratic opponent, Cal Cunningham, has highlighted Tillis’ drug pricing record throughout each of the campaign’s three debates.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.